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AbstrAct
Introduction To ease administration of medicines 
to people with dysphagia we developed and 
patented a gel formulation within which 
whole tablets could be inserted. The aim was 
to determine whether the gel would affect 
bioequivalence of uncoated aspirin tablet.
Method A gel containing gelatin, 
hydroxypropylmethylcellulose, citric acid, 
potassium sorbate and water was developed 
to maintain structure on tablet insertion and 
increase saliva production to lubricate the 
swallow.
In an open-label cross-over trial 12 healthy 
male volunteers were administered a 300 mg 
uncoated aspirin tablet with and without gel 
with a 7-day washout period. Blood salicylate 
levels, platelet activity and patient satisfaction 
were measured over 2 hours. Analysis was based 
on a random effects cross-over model.
Results The estimated mean ratio (90% CI) 
of effect on salicylate levels when comparing 
administration with and without gel was 0.77 
(90% CI 0.40 to 1.47) for amount absorbed 
and 0.76 (90% CI 0.44 to 1.31) and on total 
ASP-arachidonic acid platelet activity 1.16 
(90% CI 0.88 to 1.53) and maximum ASP-
arachidonic platelet activity 0.98 (90% CI 0.79 
to 1.22). These results are outside of the range 
allowable for the assumption of bioequivalence. 
Participants rated the taste of aspirin tablets 
significantly better when encapsulated in the gel 
(p<0.05).
Discussion We cannot assume that uncoated 
aspirin administration with and without gel is 
bioequivalent. Administration with gel resulted in 
reduced salicylate levels and therefore increased 
platelet function. Further research is required to 
determine the exact reason for this result. The 
results bring into question current processes for 
providing marketing authorisation for medical 
devices which are designed to aid swallowing.
IntroductIon
Administration of tablets and capsules in 
people with dysphagia has been shown 
to be related to a threefold increase in 
medication error rate and this is largely 
attributed to the frequent need to modify 
the solid dose formulation by crushing 
or dispersing in water prior to admin-
istration.1 Guidance frequently recom-
mends solid dose formulation alteration 
prior to administration in order to 
minimise the risk of choking and make 
oral bolus formation easier.2 Crushing 
modified release solid dose formulations 
can result in immediate dose release 
and therefore increase likelihood of 
patient harm as they receive the whole 
dose more rapidly than anticipated.3 
Similarly, disrupting enteric coatings 
can increase likelihood of harm to the 
patient’s stomach, harm to the chem-
ical entity or the drug being released 
higher up the gastrointestinal (GI) tract 
than anticipated.3 Consequently, in such 
cases, alternative routes of administra-
tion or formulations are required.4
Liquid formulations are available 
for most medicines and their prescrip-
tion immediately overcomes concerns 
regarding bolus formation in those 
with oral phase dysphagia. The texture 
of liquid medicines for patients with 
pharyngeal phase dysphagia can 
however be inappropriate as they may 
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increase the likelihood of aspiration.3 Due to the 
small market share and increased costs of production 
and storage, liquid medicines are more expensive 
than solid dose formulations and consequently cost 
is an additional barrier to their prescription.5 It is not 
possible for the liquid formulation to provide enteric 
coatings or sustained release characteristics, which 
are routinely seen with solid dose oral formulation, 
and consequently liquid medicines can require more 
frequent dosing and cannot be formulated to protect 
the stomach, active ingredients, or to ensure that 
these are released past the stomach and duodenum.
With a desire to provide patients with tablets or 
capsules intact but lubricated to ease the swallow and 
give the mouthfeel of a liquid medicine, we devel-
oped a new formulation gel which enabled tablets or 
capsules to be encapsulated prior to swallow, thereby 
removing the need for altering tablet form prior to 
administration. Using pharmaceutically inert mate-
rials, the gel (SMART Swallowing Aid) was designed 
and patented (US Patent Application No 12/866715, 
Japanese Patent Application No 2010-545564, Euro-
pean Patent Application No 09708982.5, Chinese 
Patent Application No 200980104351.4) to not react 
with the medicines or their coatings and to addition-
ally become more lubricated when in contact with 
saliva. The formulation did not contain any sugar 
making it suitable for those patients on a controlled 
diet. The SMART Swallowing Aid prototype gel was 
developed with the proposed advantages of:
 ► Increasing the comfort of the swallow.
 ► Providing lubrication to the tablet thereby negating the 
need for concomitant administration of water.
 ► Eliminating the need to crush medication.
 ► Enabling medicines designed to be absorbed further 
down the GI tract to be delivered intact.
 ► Masking the taste of the medication.
 ► Protecting the GI mucosa, in particular the oesophagus, 
to reduce oesophagitis.6
 ► Increasing the weight of the tablet and thereby aid 
passage down the oesophagus into the stomach.
 ► Minimising accusations of administering medicines 
covertly7 by ensuring that the gel was transparent.
Other tablet swallowing aids are currently available 
(Pill glide,8 Medcoat9) which are designed either to 
coat the tongue or the tablet, thereby masking the 
flavour and making it easier to swallow the medica-
tion. All products consist of ingredients, which are 
considered to be safe for humans, and are believed 
not to affect absorption of the drug from the tablet. 
Using a standard in vitro model, Medcoat has been 
shown to not adversely affect tablet disintegration.9 
While the products claim to not affect drug absorp-
tion, none have been tested in patients to determine 
bioequivalence. With concerns regarding patient 
safety and effectiveness surrounding the encapsu-
lation of a tablet prior to swallowing and a desire 
to register SMART Swallowing Aid as a medicinal 
device we decided to undertake in vivo testing.
The aim of this study was to investigate the safety, 
efficacy and acceptability of SMART Swallowing Aid 
prototype. The primary objectives of this study were 
to establish bioequivalence of aspirin with and without 
SMART Swallowing Aid (drug plasma concentration 
and drug effect on platelet activity) and test the safety 
of SMART Swallowing Aid in human subjects. As a 
secondary outcome, the study determined whether the 
gel was easy and comfortable to swallow in comparison 
with the tablet administered with water and whether it 
separated from the tablet on swallowing.
Method
The study consisted of a phase IV open-label randomised 
controlled cross-over trial, comparing the bioavailability 
of aspirin encapsulated within SMART Swallowing Aid 
with the bioavailability of aspirin alone administered 
with water.
sMArt swallowing Aid
Gelatin, from a bovine origin and certified to be 
bovine spongiform encephalopathy/transmissible 
spongiform encephalopathy free, formed the main 
ingredient as it is odourless and tasteless and forms 
a gel at room temperature and melts around body 
temperature (<35○C). To improve the gel’s swelling 
and lubrication properties hydroxypropylmethylcel-
lulose was added as it becomes less tacky on expo-
sure to water and therefore in the presence of saliva 
will lubricate the formulation. Citric acid was added 
to increase saliva production and as a preservative. 
Potassium sorbate was also included as the amount 
of citric acid was insufficient alone to prevent micro-
bial contamination. All ingredients were selected due 
to their wide routine use within pharmaceutical and 
food industries. The aspirin and gel combination was 
compared with aspirin alone in vitro via a model 
gut10 to confirm bioequivalence.
trial
The overall trial process is summarised in figure 1. 
Twelve healthy male volunteers were recruited via poster 
advertising within the University of East Anglia (UEA) 
and the Norfolk and Norwich University Hospital. 
As we expected small variation within individuals and 
we have evidence of equivalence based on lab-based 
approaches we felt that a sample size of 12 individuals 
would be sufficient to have high power to demonstrate 
bioequivalence.
The study inclusion criteria were participants who 
were:
1. Healthy.
2. Male.
3. Aged 18–35 years.
We selected only male participants as Aspirin should 
be used with caution in pregnancy and then at low 
dose. Testing in one gender also limits pharmacokinetic 
variation.
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Figure 1 Study progress flow chart. CRTU, Clinical Research 
and Trials Unit; NNUH, Norfolk and Norwich University Hospital.
Figure 2 Tablet encapsulated within SMART Swallowing Aid. 
NNUH, Norfolk and Norwich University Hospital.
The study exclusion criteria were:
1. Student at either the UEA School of Pharmacy or Med-
icine.
2. Allergy or hypersensitivity to aspirin (or other non-ste-
roidal anti-inflammatory drugs) or formulation 
ingredients.
3. Lactose intolerance or coeliac disease.
4. Dysphagia or difficulty swallowing.
5. Active peptic ulceration.
6. Haemophilia or other bleeding disorders.
7. Taking aspirin regularly or who have taken it in the last 
7 days.
8. Taking other medications, particularly those containing 
salicylates.
9. Parallel participation in another research study.
10. Related to or living with any member of the study team.
11. Language difficulties.
Participants were withdrawn if they suffered an 
adverse event or reaction in response to aspirin or the 
swallowing aid or if they demonstrated difficulty in 
swallowing using SMART. The study was planned to 
be terminated if the gel was deemed a choking hazard.
Participants were randomised using sealed enve-
lopes, which were presented in numerical order to 
each participant at the start of the first visit day. Block 
randomisation was used with a block size of 4. While 
this study could not be blinded, only the study statis-
tician was aware of the randomisation details prior to 
the visit days.
Participants attended the Clinical Research and 
Trials Unit (CRTU) based at the Norfolk and Norwich 
University Hospital having not consumed any food or 
drink for at least 2 hours prior to each visit.
Dependent on randomised allocation each partici-
pant was asked to swallow either one SMART Swal-
lowing Aid containing one 300 mg aspirin uncoated 
tablet (figure 2), or to swallow one 300 mg aspirin 
uncoated tablet with a glass of potable water.
Aspirin should be taken with food to avoid the 
risk of stomach ulceration, and consequently to stan-
dardise stomach contents prior to administration all 
participants were given two Weetabix on arrival with 
a measured volume of semiskimmed milk. Aspirin is 
known to exhibit a half-life of 15–20 min, with that 
of its metabolite salicylate being 3–6 hours. A washout 
period of 1 week allowed elimination of aspirin and 
its metabolite in the region of 504 and 28 half-lives, 
respectively, which was adequate for the purposes of 
this study. Participants were asked not to take aspirin 
or any medications containing aspirin or salicylates for 
7 days prior to each data collection event and this was 
confirmed on arrival at the visit day.
Venous blood samples were taken at time 0 and 
20, 40, 60, 90 and 120 min after the dose.11 Serum 
salicylate levels were measured with Advia 2400, Clin-
ical Chemistry System by contract research company 
Viapath, Kings College, London.12 Platelet function 
was measured by impedance aggregometry using 
the Multiplate system (Verum Diagnostica, Munich, 
Germany).13 Platelet function included both measure-
ments of effect on arachidonic acid and collagen.
Participants completed a questionnaire after taking 
the tablet with SMART Swallowing Aid and after 
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Figure 3 Visit progress flow chart.
taking the tablet with water. Questionnaires consisted 
of three visual analogue scales (VAS) in response 
to ‘The tablet was easy to swallow’, ‘The tablet was 
comfortable to swallow’ and ‘I could taste the tablet 
during the swallow’. The lower the score the more 
positive the response. Additionally, a single yes/no 
question ‘The gel aid broke/the tablet separated from 
the gel aid’ was included when the tablet was adminis-
tered with the gel.
Participants then returned after at least 1 week to 
repeat the study with the alternative method of admin-
istration and were remunerated for their participa-
tion. The process within the CRTU is summarised in 
figure 3.
outcomes
The outcome measures were: (1) the maximum 
concentration of salicylate; (2) area under the curve 
(AUC) of the concentration of salicylate (salicylate 
concentration measured at 0, 20, 40, 60, 90 and 120 
min after swallowing); (3) the maximum collagen; (4) 
the AUC of the collagen; (5) the maximum ASP-arachi-
donic acid AUC; and (6) the AUC of ASP-arachidonic 
acid. Collagen AUC and ASP-arachidonic acid AUC are 
measured at 0, 20, 60 and 120 min after swallowing.
data analysis
Analysis was undertaken using the software package 
SAS 9.4.
Data generated from the participant taking SMART 
Swallowing Aid will be referred to as T (or test) and 
the data generated from the participant taking the 
non-gel as R (or reference).
derived variables
The AUC for aspirin serum concentration was calcu-
lated using the trapezoidal rule using the equation:
 
AUC =
(
C0+C20
)
2 × 20 +
(
C20+C40
)
2 × 20 +
(
C40+C60
)
2 × 20
+
(
C60+C90
)
2 × 30 +
(
C90+C120
)
2 × 30  
where Ct is the aspirin serum concentration at time 
t. Any missing or incomplete data were replaced using 
last observation carried forward in order to calculate 
the AUC.
AUC for the platelet function test was calculated in 
a similar fashion.
Cmax for both aspirin serum concentration and 
platelet function test was calculated as the maximum 
value of the variables at the observed time points.
As an equivalence study, only individuals who 
adhered to the protocol were included in the analysis.
Average bioequivalence
In order to demonstrate average bioequivalence (ABE), 
both the mean AUC and the mean Cmax for treatment 
should not significantly differ from the mean AUC 
and mean Cmax for control using a two one-sided 
test procedure. The trial team set the limits that ABE 
would be demonstrated if the 90% two-sided CI for 
the mean difference falls within the acceptance limits 
of –ln(1.25).14 To be precise, if µT denotes the true 
mean log(AUC) {or log(Cmax)} for those with the 
test and µR for those with the reference group, ABE is 
demonstrated if there is good evidence that:
 0.8 ≤ exp
(
µT − µR
) ≤ 1.25 
The model used to estimate ABE was based on a 
random effects cross-over model using the Kenward-
Roger df.14
Population bioequivalence
The level of both population bioequivalence (PBE) was 
measured using the standard guidelines issued from 
the Food and Drug Administration and estimated using 
a mixed model approach to estimate the within-subject 
variances required for the measured PBE. For PBE, the 
metric is given by equation whose 90% CI must be 
below zero.14
For all ABE and PBE and random effects (partici-
pants as random), a cross-over model was used to esti-
mate the required parameters. The aggregate measures 
are functions of the estimated variances and easily 
calculable from the computer output.
It is not possible to estimate the power of this study 
since there are not enough data on which to base an 
estimate of the within-subject SD. Although given that 
SMART Swallowing Aid is unlikely to have a large 
impact on the AUC or Cmax, the within-subject SD 
was likely to be small and hence the power was likely 
to be high. It should be noted, however, that cross-over 
trials used to assess for PBE generally use in excess of 
20–30 subjects so these results may be more explor-
atory than confirmatory.
Questionnaire analysis
The ease of swallowing and the comfort of swallowing 
and taste obtained from the questionnaires were anal-
ysed using a non-parametric Mann-Whitney test.
regulatory approvals
The trial was registered with EudraCT 2011-
005208-14 and ISRCTN 13972867.
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table 1 Summary statistics of outcome measures
Sequence
no gel/with gel With gel/no gel
Period 1 Period 2 Period 1 Period 2
Log AUC collagen 8.98 (0.19) 9.04 (0.19) 8.98 (0.21) 8.86 (0.18)
Log Cmax 
collagen
4.43 (0.13) 4.42 (0.12) 4.37 (0.23) 4.24 (0.11)
Log AUC ASP-
arachidonic acid
8.80 (0.42) 8.98 (0.33) 8.76 (0.54) 8.63 (0.24)
Log Cmax ASP-
arachidonic acid
4.66 (0.22) 4.59 (0.17) 4.41 (0.52) 4.38 (0.18)
Log AUC 
salicylate
6.02 (1.07) 6.25 (0.83) 5.61 (1.06) 6.36 (0.66)
Log Cmax 
salicylate
2.24 (0.86) 2.40 (0.74) 1.83 (0.82) 2.55 (0.54)
ASP, aspirin; AUC, area under the curve.
table 2 Estimate of ratio of means (with gel/no gel) and 90% 
CI
Variable
estimate of mean 
ratio 90% Ci
Log AUC collagen 1.09 (0.96 to 1.24)
Log Cmax collagen 1.07 (0.99 to 1.16)
Log AUC ASP-arachidonic acid 1.16 (0.88 to 1.53)*
Log Cmax ASP-arachidonic acid 0.98 (0.79 to 1.22)*
Log AUC salicylate 0.77 (0.40 to 1.47)*
Log Cmax salicylate 0.76 (0.44 to 1.31)*
*Outside of range allowable to enable assumption of bioequivalence.
ASP, aspirin; AUC, area under the curve.
Figure 4 Salicylate concentration (mg/L) over time for 
uncoated aspirin administered with and without gel.
Figure 5 Collagen platelet activity over time for uncoated 
aspirin administered with and without gel.
results
Twelve healthy male volunteers were randomised to 
receive either ‘Gel/no gel’ or ‘No gel/gel’. All partici-
pants who were randomised finished the trial and no 
participant was lost to follow-up. All participants took 
the intervention as intended and no adverse events 
were observed during the course of this trial.
The analysis was performed in compliance with the 
statistical analysis plan, due to the nature of bioequiva-
lence it is necessary to know the treatment (T) and the 
reference (R) so this analysis was not blinded.
bioequivalence results
A summary of the outcome measure at the end of each 
period is given in table 1. This shows roughly equal 
means for collagen and ASP-arachidonic acid in each 
period and each sequence, but a slight difference in 
salicylate AUC and Cmax.
ABE results are presented in table 2. These have 
been estimated based on random effects cross-over 
model using the Kenward-Roger df.14 These show 
that since the 90% CI does not fall within the (0.80, 
1.25) window, ABE cannot be concluded. The change 
in salicylate concentrations, collagen and ASP-arachi-
donic acid activity over time is shown in figures 4–6, 
respectively. The figures show an increase in salicylate 
levels and corresponding reduction in platelet activity 
as measured by ASP-arachidonic acid, but limited or 
no change in platelet activity as measured by collagen. 
Giving the aspirin with the gel results in lower salicy-
late concentrations and higher platelet activity.
PBE was estimated using the metric provided in Jones 
and Kenward (2003, p 343).14 This metric is essentially 
a combination of the mean difference (squared) and 
the variances of the treatment response. The important 
factor is the upper 90% CI bound for the metric. If 
this is below zero then PBE can be declared. It should 
be noted that if ABE has not been demonstrated it is 
unlikely that PBE can be demonstrated. The values for 
each outcome are given in table 3. These show that T 
and R are PBE for collagen, but not for ASP-arachi-
donic acid or salicylate.
Questionnaire results
The summary of the questionnaire VAS responses and 
formal comparisons is given in table 4. This shows that 
there is a significant treatment effect for taste with the 
gel group having a lower mean score than the no gel 
group. Out of the 12 individuals, 11 reported that the 
gel did not break and one reported that ‘first tablet 
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Figure 6 ASP-Arachidonic acid platelet activity over time for 
uncoated aspirin administered with and without gel.
table 3 Lower 90% CI bound for PBE metric
Variable
lower 
bound
Log AUC collagen −0.01
Log Cmax collagen −0.02
Log AUC ASP-arachidonic acid 0.19*
Log Cmax ASP-arachidonic acid 0.16*
Log AUC salicylate 0.54*
Log Cmax salicylate 0.44
*Outside of range allowable to enable assumption of bioequivalence.
ASP, aspirin; AUC, area under the curve; PBE, population bioequivalence.
table 4 Summary statistics of questionnaire data
Sequence
P 
value
Carry-
over P 
value
no gel/with gel With gel/no gel
Period 
1 Period 2 Period 1 Period 2
Ease of 
swallowing
9.55 
(0.4)
8.73 
(1.59)
7.48 
(2.07)
9.05 
(1.08)
0.1495
Comfort 9.13 
(1.50)
7.75 
(1.97)
8.93 
(0.77)
9.22 
(1.23)
0.1087
Taste 4.73 
(4.57)
0.58 
(0.62)
1.47 
(1.54)
4.42 
(4.35)
0.0370 0.5204
spat out as it separated from gel, second tablet didn't 
separate.’
dIscussIon
The study successfully recruited to target with no 
dropout. There were no safety issues identified during 
the trial. It cannot, however, be stated that bioequiv-
alence was demonstrated when taking aspirin with 
and without the gel. The salicylate levels and amount 
absorbed seemed to be greater without the gel, which 
corresponded with lower platelet function test results. 
As anticipated, the patients who swallowed aspirin 
coated in the gel found the taste to be better. Further-
more, although water was not provided with the 
aspirin tablet when it was coated in the gel no signifi-
cant effect on ease of swallow or swallow comfort was 
detected.
As a randomised controlled cross-over study we 
were able to use a relatively small sample size to detect 
reasonable differences in bioequivalence. Although 
the trial was open label and this was unavoidable due 
to the nature of what was being tested we would not 
expect this to adversely affect clinical biomarkers.
We chose to give Weetabix prior to administration 
of the tablet with and without gel as the trial occurred 
in the morning and this is a common breakfast within 
the UK. As a randomised control cross-over trial any 
effect that it may have itself on absorption will have 
been taken into account.
While we followed a previously reported process 
for undertaking an evaluation to assess salicylate levels 
after dose, the results show that we did not capture 
the full pharmacokinetic profile.11 Tmax for normal 
coated aspirin is 2 hours15 and therefore considering 
the results seen, either the Cmax or Tmax is unlikely 
to be the same for aspirin when given with or without 
gel.
The results suggest therefore that the gel may be 
reducing aspirin absorption, resulting in increased 
platelet activity. Our in vitro test for bioequivalence 
identified an average difference of 6 s in disintegra-
tion time and this we did not deem sufficient to signifi-
cantly affect bioequivalence. The encapsulation may, 
however, be delaying the release of aspirin in vivo more 
than that identified in vitro and a longer follow-up time 
may have resulted in similar total aspirin release. An 
alternative hypothesis may be that the water content 
in the gel, which is in close contact with the uncoated 
tablet, may be hydrolysing the aspirin and therefore 
making less available for absorption and metabolism 
to salicylate in the first instance. Finally, an ingredient 
within the gel itself may be incompatible with aspirin 
and either physically or chemically interacting with the 
molecule to reduce absorption. The ingredients were 
selected due to their largely inert nature, however this 
may not be the case with this specific molecule.
While one option maybe to test the gel with different 
medicines which are known to be less susceptible to 
water or less likely to break down before the gel is 
absorbed, we would suggest that it would be more effi-
cient to reformulate the gel to ensure that it is unlikely 
to affect absorption of all medicines.
The finding that reductions in aspirin levels were 
related to increased platelet function as measured by 
arachidonic acid is to be expected as this is seen as 
an appropriate measure for this purpose16 whereas 
platelet binding to a collagen surface has been shown 
to be less sensitive to changes in aspirin levels.17
It could be argued that we selected a chemical 
entity and formulation which was more likely to be 
affected by the encapsulation and therefore this may 
not have provided an ideal model. However, aspirin 
was selected because it is frequently prescribed in indi-
viduals with dysphagia and due to it being very likely 
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to react with ingredients and therefore a positive result 
would have provided greater reassurance regarding the 
inert nature of the gel.
The results bring into question the fact that other 
similar products have been allowed to be marketed to 
be used to ease medication administration without in 
vivo testing. Recent research has shown that mixing 
medicines’ food thickeners significantly reduces their 
effectiveness18 19 and although the extent of interac-
tion and contact with swallowing aids and medicines 
is less, it seems that the likelihood of interaction needs 
to be explored more extensively prior to award of 
marketing authorisation.
We therefore have to conclude that in using the 
gel to enable aspirin to be swallowed without either 
crushing or the addition of water we cannot assume 
bioequivalence and therefore further research is 
required to determine the exact reason for this result 
and to develop a product, which is less likely to affect 
bioequivalence.
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